Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 2/20 | 0.36 |
| ▸ | NOS2 | P35228 | 1/20 | 0.36 |
| ▸ | HTR2C | P28335 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | PNMT | P11086 | 1/20 | 0.32 |
| ▸ | CD44 | P16070 | 1/20 | 0.32 |
| ▸ | MAOB | P27338 | 1/20 | 0.32 |
| ▸ | MAOA | P21397 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17193188 | 0.87 | TSHR (0.42) | NOS3NOS2HTR2CTSHRPNMT | |
| SCHEMBL4175339 | 0.76 | — | — | |
| SCHEMBL1162633 | 0.73 | NOS3 (0.36) | NOS3NOS2HTR2CTSHRMAOA | |
| SCHEMBL17193192 | 0.68 | TSHR (0.40) | NOS3NOS2HTR2CTSHRPNMT | |
| SCHEMBL8912020 | 0.67 | TSHR (0.43) | NOS3NOS2HTR2CTSHRPNMT | |
| SCHEMBL31251596 | 0.67 | TSHR (0.43) | NOS3NOS2HTR2CTSHRPNMT | |
| SCHEMBL1751341 | 0.67 | TSHR (0.43) | NOS3NOS2HTR2CTSHRPNMT | |
| SCHEMBL11095966 | 0.67 | TSHR (0.43) | NOS3NOS2HTR2CTSHRPNMT | |
| SCHEMBL327799 | 0.67 | TSHR (0.43) | NOS3NOS2HTR2CTSHRPNMT | |
| SCHEMBL2512554 | 0.65 | MEN1 (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 775 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4399216-A1 | IMMUNOMODULATING AZALIDES | Zoetis Services LLC (US) | 2024-07-17 | — | — | EP | claimed |
| CN-118139870-A | Immunomodulatory nitrogen ring lactones | 硕腾服务有限责任公司 | 2024-06-04 | — | — | CN | claimed |
| US-20230129040-A1 | IMMUNOMODULATING AZALIDES | ZOETIS SERVICES LLC | 2023-04-27 | — | — | US | claimed |
| WO-2023038852-A1 | IMMUNOMODULATING AZALIDES | ZOETIS SERVICES LLC (US) | 2023-03-16 | — | — | WO | claimed |
| CN-108727369-A | Inhibitors of influenza viruses replication and application thereof | 广东东阳光药业有限公司 | 2018-11-02 | — | — | CN | claimed |
| US-20180312496-A1 | BICYCLIC HETEROCYCLE DERIVATIVES AS BROMODOMAIN INHIBITORS | ORION CORP (FI) | 2018-11-01 | — | — | US | claimed |
| EP-3317266-A1 | BICYCLIC HETEROCYCLE DERIVATIVES AS BROMODOMAIN INHIBITORS | Orion Corporation (FI) | 2018-05-09 | — | — | EP | claimed |
| CN-104936962-B | Therapeutically active oxazoline derivatives | UCB生物制药私人有限公司 | 2017-02-22 | — | — | CN | claimed |
| WO-2017001733-A1 | BICYCLIC HETEROCYCLE DERIVATIVES AS BROMODOMAIN INHIBITORS | ORION CORPORATION (FI) | 2017-01-05 | — | — | WO | claimed |
| US-9505753-B2 | Inhibitors of D-amino acid oxidase | THE JOHNS HOPKINS UNIVERSITY (US) | 2016-11-29 | — | — | US | claimed |
| WO-1996039382-A1 | UREA DERIVATIVES AS 5-HT ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1996-12-12 | — | — | WO | claimed |
| US-5567709-A | IMMUNOSUPPRESSANTS | AMERICAN HOME PRODUCTS CORPORATION (US) | 1996-10-22 | — | — | US | claimed |
| US-5559119-A | IMMUNOSUPPRESSANTS, ANTIINFLAMMATORY AGENTS, FUNGICIDES AND ANTITUMOR AGENTS | AMERICAN HOME PRODUCTS CORPORATION (US) | 1996-09-24 | — | — | US | claimed |
| US-5559112-A | IMMUNOSUPPRESSANTS, ANTIINFLAMMATORY AGENTS, FUNGICIDES AND ANTITUMOR AGENTS | AMERICAN HOME PRODUCTS CORPORATION (US) | 1996-09-24 | — | — | US | claimed |
| US-5532355-A | IMMUNOSUPPRESSANTS FOR ORGAN TRANSPLANTS | AMERICAN HOME PRODUCTS CORPORATION (US) | 1996-07-02 | — | — | US | claimed |
| US-5519031-A | TREATMENT OF RESTENOSIS, IMMUNOSUPPRESIVE AGENTS, ANTIINFLAMMATORY AGENTS, FUNGICIDES OR ANTITUMOR AGENTS | AMERICAN HOME PRODUCTS CORPORATION (US) | 1996-05-21 | — | — | US | claimed |
| US-5516780-A | IMMUNOSUPPRESSIVE, ANTIINFLAMMATORY, ANTIFUNGAL AND ANTITUMOR AGENTS | AMERICAN HOME PRODUCTS CORPORATION (US) | 1996-05-14 | — | — | US | claimed |
| US-5434260-A | Treating transplantation rejection in mammals | AMERICAN HOME PRODUCTS CORPORATION (US) | 1995-07-18 | — | — | US | claimed |
| US-4649146-A | ANTIULCER | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1987-03-10 | — | — | US | claimed |
| US-4113867-A | ANTHELMINTICS | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1978-09-12 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180312496-A1 | BICYCLIC HETEROCYCLE DERIVATIVES AS BROMODOMAIN INHIBITORS | BRD1, BRD4, BRD2 | NOS3 3793/4885NOS2 3110/4885HTR2C 1768/4885 |
| US-20230129040-A1 | IMMUNOMODULATING AZALIDES | IL2, MALT1, FCGRT | NOS3 1003/4885NOS2 503/4885HTR2C 4578/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.